Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 2
Submit an article Journal homepage
520
Views
0
CrossRef citations to date
0
Altmetric
Research Article

CYP3A4 Intron 6 C>T SNP (CYP3A4*22) Encodes Lower CYP3A4 Activity in Cancer Patients, as Measured with Probes Midazolam and Erythromycin

Laure Elens1 Department of Clinical Chemistry, Erasmus University Medical Center, PO Box 2040, 3000CA Rotterdam, The Netherlands;2 Louvain Centre for Toxicology & Applied Pharmacology, Université Catholique de Louvain, Brussels, Belgium
,
Annemieke Nieuweboer3 Department of Medical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
,
Stephen J Clarke4 University of Sydney, Sydney, New South Wales, Australia
,
Kellie A Charles4 University of Sydney, Sydney, New South Wales, Australia
,
Anne-Joy de Graan3 Department of Medical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
,
Vincent Haufroid2 Louvain Centre for Toxicology & Applied Pharmacology, Université Catholique de Louvain, Brussels, Belgium
,
Ron HJ Mathijssen3 Department of Medical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
&
Ron HN van Schaik1 Department of Clinical Chemistry, Erasmus University Medical Center, PO Box 2040, 3000CA Rotterdam, The Netherlands
 show all
Pages 137-149 | Published online: 17 Jan 2013

References

  • Danielson PB . The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab.3(6) , 561–597 (2002).
  • Lamba JK , LinYS, SchuetzEG, ThummelKE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54(10) , 1271–1294 (2002).
  • Shimada T , GuengerichFP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl Acad. Sci. USA86(2) , 462–465 (1989).
  • Westlind A , LofbergL, TindbergN, AnderssonTB, Ingelman-SundbergM. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5´-upstream regulatory region. Biochem. Biophys. Res. Commun.259(1) , 201–205 (1999).
  • Westlind-Johnsson A , MalmeboS, JohanssonA et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31(6) , 755–761 (2003).
  • Chiou WL , JeongHY, WuTC, MaC. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin. Pharmacol. Ther.70(4) , 305–310 (2001).
  • Mathijssen RH , LoosWJ, VerweijJ. Determining the best dose for the individual patient. J. Clin. Oncol.29(33) , 4345–4346 (2011).
  • Ozdemir V , KalowW, TangBK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5) , 373–388 (2000).
  • Baker SD , van Schaik RH, Rivory LP et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res.10(24) , 8341–8350 (2004).
  • Ball SE , ScatinaJ, KaoJ et al. Population distribution and effects on drug metabolism of a genetic variant in the 5´ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3) , 288–294 (1999).
  • Floyd MD , GervasiniG, MasicaAL et al. Genotype–phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European– and African–American men and women. Pharmacogenetics 13(10) , 595–606 (2003).
  • He P , CourtMH, GreenblattDJ, Von Moltke LL. Genotype–phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther.77(5) , 373–387 (2005).
  • Kharasch ED , WalkerA, IsoherranenN et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther. 82(4) , 410–426 (2007).
  • Lepper ER , BakerSD, PermenterM et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin. Cancer Res. 11(20) , 7398–7404 (2005).
  • Miao J , JinY, MarundeRL et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9(5) , 319–326 (2009).
  • Shih PS , HuangJD. Pharmacokinetics of midazolam and 1´-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos.30(12) , 1491–1496 (2002).
  • Tomalik-Scharte D , DoroshyenkoO, KirchheinerJ et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur. J. Clin. Pharmacol. 64(10) , 1033–1035 (2008).
  • Wandel C , WitteJS, HallJM, SteinCM, WoodAJ, WilkinsonGR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5´-promoter region polymorphism. Clin. Pharmacol. Ther.68(1) , 82–91 (2000).
  • Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
  • Elens L , BeckerML, HaufroidV et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12) , 861–866 (2011).
  • Elens L , BouamarR, HesselinkDA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11) , 1574–1583 (2011).
  • Elens L , BouamarR, HesselinkDA, HaufroidV, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics22(5) , 373–380 (2012).
  • Elens L , van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors‘ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics12(10) , 1383–1396 (2011).
  • Staatz CE , GoodmanLK, TettSE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin. Pharmacokinet.49(4) , 207–221 (2010).
  • Staatz CE , GoodmanLK, TettSE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet.49(3) , 141–175 (2010).
  • Mathijssen RH , van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur. J. Cancer42(2) , 141–148 (2006).
  • Rogers JF , RocciML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin. Pharmacol. Ther.73(3) , 153–158 (2003).
  • Streetman DS , BertinoJS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics10(3) , 187–216 (2000).
  • Gorski JC , HallSD, JonesDR, VandenbrandenM, WrightonSA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol.47(9) , 1643–1653 (1994).
  • He P , CourtMH, GreenblattDJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab. Dispos.34(7) , 1198–1207 (2006).
  • Patki KC , von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos.31(7) , 938–944 (2003).
  • Rivory LP , SlavieroKA, HoskinsJM, ClarkeSJ. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet.40(3) , 151–158 (2001).
  • Rivory LP , WatkinsPB. Erythromycin breath test. Clin. Pharmacol. Ther.70(4) , 395–399 (2001).
  • Cakaloglu Y , TredgerJM, DevlinJ, WilliamsR. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology20(2) , 309–316 (1994).
  • Lown KS , ThummelKE, BenedictPE et al. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57(1) , 16–24 (1995).
  • Turgeon DK , NormolleDP, LeichtmanAB, AnnesleyTM, SmithDE, WatkinsPB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther.52(5) , 471–478 (1992).
  • Watkins PB . Noninvasive tests of CYP3A enzymes. Pharmacogenetics4(4) , 171–184 (1994).
  • Watkins PB , HamiltonTA, AnnesleyTM, EllisCN, KolarsJC, VoorheesJJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther.48(2) , 120–129 (1990).
  • Gorski JC , JonesDR, Haehner-DanielsBD, HammanMA, O‘MaraEM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther.64(2) , 133–143 (1998).
  • Kronbach T , MathysD, UmenoM, GonzalezFJ, MeyerUA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol.36(1) , 89–96 (1989).
  • Wandel C , BockerR, BohrerH, BrowneA, RugheimerE, MartinE. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth.73(5) , 658–661 (1994).
  • Wrighton SA , BrianWR, SariMA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38(2) , 207–213 (1990).
  • Hirth J , WatkinsPB, StrawdermanM, SchottA, BrunoR, BakerLH. The effect of an individual‘s cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res.6(4) , 1255–1258 (2000).
  • Rivory LP , SlavieroK, SealeJP et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6(9) , 3480–3485 (2000).
  • van der Bol JM , MathijssenRH, CreemersGJ et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16(2) , 736–742 (2010).
  • Mathijssen RH , de Jong FA, van Schaik RH et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl Cancer Inst.96(21) , 1585–1592 (2004).
  • Chaobal HN , KharaschED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther.78(5) , 529–539 (2005).
  • Kim JS , NafzigerAN, TsunodaSM et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol. 42(4) , 376–382 (2002).
  • Nguyen AN , HoffmanJT, TsunodaSM, JangIJ, MaJD. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int. J. Clin. Pharmacol. Ther.50(7) , 468–475 (2012).
  • Wong M , BalleineRL, CollinsM, LiddleC, ClarkeCL, GurneyH. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther.75(6) , 529–538 (2004).
  • Kurnik D , WoodAJ, WilkinsonGR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther.80(3) , 228–234 (2006).
  • Lan LB , DaltonJT, SchuetzEG. Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol.58(4) , 863–869 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.